Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

200981 citationsJournal Article

Authors

Good health and well-being

Published in: European Journal of Cancer

Volume 45, Issue 13, pp. 2333-2341

Field-Weighted Citation Impact: 3.39